Daewoong Pharmaceutical Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Daewoong Pharmaceutical Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Daewoong Pharmaceutical Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Daewoong Pharmaceutical Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Daewoong Pharmaceutical Co Ltd (Daewoong Pharmaceutical), a subsidiary of Daewoong Co Ltd, is a manufacturer and distributor of prescription drugs. The company offers prescription drugs, quasi drugs, healthcare products and APIs. It produces products in the form of tablets, capsules, ointments, injections, liquids, and sprays. It offers products for conditions such as bone and joint diseases, cardiovascular diseases, central nervous system diseases, circulatory system, dermatological, gastrointestinal, and respiratory system remedies. It also carries out the development and commercialization of products through in-licensing, co-marketing and co-promotion. The company operates in Japan, the US, Canada, Switzerland, Germany, Indonesia, China, Vietnam, Israel, Thailand, and India. Daewoong Pharmaceutical is headquartered in Seoul, South Korea.
Headquarters
South Korea
Address
35-14, Jeyakgongdan 4-Gil, Hyangnam-Eup, Hwaseong, 18623
Website
www.daewoong.co.kr
Telephone
82 25508800
No of Employees
1,749
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
069620 (KRX)
Revenue (2024)
$1.1B
10.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
691.8%
(2024 vs 2023)
Market Cap*
$1.1B
Net Profit Margin (2024)
XYZ
616.7%
(2024 vs 2023)
* As of and is in US$
Daewoong Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Over the counter Drugs | CDMO Service | Nabota |
| Prescription Drugs | CareTropin | |
| Generics | Novosis | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | New Products/Services | In December, the company announced the launch of Pexuclu 20mg, to prevent gastric ulcers in patients taking anti-inflammatory painkillers long-term. |
| 2025 | Others | In December, the company applied to the Animal and Plant Quarantine Agency for product approval for a canine atopic dermatitis treatment containing the active ingredient flodicitinib. |
| 2025 | New Products/Services | In November, the company announced the launch of tofacitinib formulation, Zeltopa, to target the autoimmune disease market. |
Competitor Comparison
| Key Parameters | Daewoong Pharmaceutical Co Ltd | Yuhan Corp | GC Biopharma Corp | Dong-A Socio Holdings Co Ltd | Huons Global Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Hwaseong | Seoul | Yongin-si | Seoul | Seongnam |
| No. of Employees | 1,749 | 1,594 | 2,355 | 273 | 541 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Changjae Lee | Co-Chief Executive Officer | Senior Management | 2022 | 48 |
| Park Seong-su | Co-Chief Executive Officer | Senior Management | 2023 | 49 |
| Hong Seung-suh | Head - Biosimilar Division | Senior Management | 2025 | - |
| Hong Seung-seo | Head - BS Institutional Sector | Senior Management | 2025 | - |
| Sungsoo Park | Director | Non Executive Board | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer